Removing the guessing game
At Ignite Biomedical, we're revolutionizing the approach to PsA management. Our focus is on developing precision Treatment Response Predictors (TRPs) using Liquid Bioscience’s innovative Emerge® AI platform to identify novel biomarkers associated with PsA. This technology allows us to:
- Predict which patients are most likely to benefit from specific PsA treatments
- Reduce unnecessary medical interventions and their associated side effects
- Minimize healthcare waste
- Improve long-term patient outcomes
We understand that current treatments, while beneficial for some, leave many patients without optimal relief. That's why we're leveraging our cutting-edge AI technology to create personalized treatment plans that address both joint and skin symptoms.
Our goal is to provide clinicians and patients with objective, data-driven decision support tools that can transform PsA care. By moving beyond the traditional trial-and-error approach, we aim to improve treatment efficacy, reduce time to remission, and enhance overall quality of life for those living with psoriatic arthritis.
At Ignite, we're not just developing tests; we're pioneering a patient-focused approach to managing PsA, bringing us closer to the promise of true precision medicine in rheumatology and dermatology.
Psoriatic arthritis (PsA)
Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune condition characterized by joint inflammation, often occurring in people with psoriasis. It can affect various joints, including those in the fingers, toes, back, and pelvis. Symptoms typically include joint pain, stiffness, and swelling, as well as skin and nail changes associated with psoriasis.
.png)